Hematologic Cancer Program

Our department

The Hematologic Malignancies and Stem Cell Transplant Program at Cancer Treatment Centers of America® (CTCA), Chicago, provides standard-of-care and, when appropriate, advanced medical therapies for hematologic (blood) disorders, including leukemianon-Hodgkin lymphomaHodgkin lymphomamultiple myeloma and myelodysplastic syndromes.

Treatment options

Treatment for hematologic cancers depends on a number of factors, such as the type of cancer, your age, how fast the cancer is progressing and if and where the cancer has spread. The Hematologic Malignancies and Stem Cell Transplant Program at CTCA Chicago offers patients a number of treatment options, including:

Chemotherapy uses anti-cancer drugs to interfere with and stop the growth of cancer cells in the body. Chemotherapy for blood cancers sometimes involves giving several drugs together in a set regimen. This treatment may also be given before a stem cell transplant.

Radiation therapy may be used to destroy cancer cells or to relieve pain or discomfort. It may also be given before a stem cell transplant.

Immunotherapy drugs may be used to treat specific types of blood cancers. Some immunotherapies, called immunomodulating drugs, affect parts of the immune system.

Stem cell transplantation infuses healthy blood-forming stem cells into the body. Stem cells may be collected from the bone marrow, circulating blood and umbilical cord blood.

Learn more about the blood cancers we treat

FACT-accredited program

CTCA Chicago is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), which is the threshold for excellence in cellular therapy, including bone marrow or cord blood transplantation. FACT, an internationally recognized accrediting body for hospitals and medical institutions that perform stem cell transplants, recognizes excellence by facilities that meet rigorous standards, including those on clinical care, donor management, apheresis collection, processing, storage, transportation, autologous administration and cell release.


Stem cell transplantation

A stem cell transplant may be used to infuse healthy stem cells into the body to stimulate new bone marrow growth, suppress the disease and reduce the possibility of a relapse. Stem cells are drawn from the bone marrow, circulating blood (peripheral blood stem cells) and umbilical cord blood.

If stem cell transplantation is a necessary part of your treatment plan, the Hematologic Malignancies and Stem Cell Transplant Program at CTCA Chicago offers a comprehensive array of therapies and transplantation services, including autologous (individual’s own cells), allogeneic (donor cells), and adoptive immunotherapies, which is a treatment approach that uses an individual’s own (autologous) or donor (allogeneic) white blood cells as a proposed treatment for various malignancies.

Patients who require stem cell transplantation will stay in one of our private, inpatient rooms and receive around-the-clock monitoring and care. Your care team will include a board-certified hematologic oncologist who is a bone marrow transplant physician, as well as a hematopathologist, nurse care manager, transplant pharmacist and transplant coordinator. The team is dedicated to making sure you and your family are comfortable throughout your stay.

National Marrow Donor Program 

Be The Match
CTCA Chicago is a member of the National Marrow Donor Program (NMDP)
and an approved NMDP Transplant and Collection Center.

To learn more about the NMDP or for more information about
becoming a donor or finding a match, visit the Be The Match website
or call 800-MARROW-2 (800-627-7692).

Meet our team

The CTCA Chicago Hematologic Malignancies and Stem Cell Transplant Program experts are committed to offering integrative, personalized treatments for blood-related diseases. Explore the links below to learn more about the team.

Istvan Redei - Chief, Division of Stem Cell Transplantation, Department of Medical Oncology at Cancer Treatment Centers of America®

Istvan Redei

Director, Hematologic Malignancies and Stem Cell Transplant Program, CTCA Chicago

Syed A. Abutalib - Assistant Director, Stem Cell Transplant & Cell Therapy Program, Hematologist & Medical Oncologist

Syed A. Abutalib

Associate Medical Director, Hematologic Malignancies and Stem Cell Transplant Program, CTCA Chicago

Bradford Tan - Chair Department of Pathology and Laboratory Medicine

Bradford Tan

Chair, CTCA Department of Pathology and Laboratory Medicine, Chief of Staff, CTCA Chicago

Jianping Lin

Pathologist, CTCA Chicago

Delu Zhou - Pathologist

Delu Zhou

Pathologist, CTCA Chicago

A comprehensive, integrative team approach

Our Hematologic Malignancies and Stem Cell Transplant Program team has expertise in diagnosing and treating hematologic diseases using sophisticated technologies and therapies delivered through a personalized approach and customized to meet your needs. Our program includes both inpatient and outpatient treatment options.

When you first visit the hospital, you’ll meet with your program team, which includes a board-certified hematologic oncologist, to evaluate your condition and review your medical records. Your hematologic oncologist will then determine whether additional diagnostic tests, such as lab work, a bone marrow biopsy or imaging scans, are required before determining a treatment plan.

Once in treatment, you and your family are cared for by a multidisciplinary team of experts and specialists. Your care is directly managed by one or more of our board-certified hematologic oncologists who work together with the entire team. A nurse care manager will help you navigate through questions or concerns.

You will also have access to an array of integrative care services, such as nutritional, naturopathic, psychosocial and spiritual support, as well as other services focused on helping you manage side effects, recover from treatment and improve your quality of life.

Learn more about the value of integrated cancer care

Adrain M

Adrian M.

Hodgkin Lymphoma

"I am thankful for CTCA. I felt genuine concern and empathy from the doctors and nurses. No one made me feel silly about the questions I had, and they were all thoughtfully answered. As I continue my care at CTCA, I know my doctors and everyone there truly cares about me and my well-being. I am not just a number—they all know me and my family. That alone is extraordinary to me."


More About ADRIAN

Clinical trials

Cancer clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases.

The hematologic oncologists working with patients treating at the Hematologic Malignancies and Stem Cell Transplant Program are committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer.

As part of that commitment, your hematologic oncologist may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Although clinical trials are not available to all patients, they may offer some patients options that would otherwise be unavailable to them. Your care team will discuss whether you qualify for any of our ongoing clinical trials or any at the national level, and if so, help you enroll.

Learn more about the CTCA clinical trials program and which trials are available


Where we are located

CTCA Chicago

Hematologic Malignancies and Stem Cell Transplant Program
2520 Elisha Ave.
Zion, IL 60099

New Patients: 866-368-0461
Existing Patients: 847-510-CTCA
Get directions

Outpatient Care Center, Gurnee

202 S. Greenleaf St., Suite E
Gurnee, IL 60031
New Patients: 866-368-0461
Existing Patients: 847-857-CTCA

Get directions